Clinical Report: First MCT8 deficiency therapy approved

Overview

The FDA has approved tiratricol (Emcitate) for treating peripheral thyrotoxicosis in patients with MCT8 deficiency.

Background

Monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan-Herndon-Dudley syndrome, is a rare genetic disorder that impacts thyroid hormone transport, leading to neurodevelopmental impairments. The condition primarily affects males and results in symptoms such as intellectual disability and feeding difficulties. Treatment options have been limited.

Data Highlights

Tiratricol was evaluated in two clinical studies, including a randomized, placebo-controlled trial and a long-term open-label study, demonstrating its efficacy in lowering circulating thyroid hormone levels and improving cardiovascular symptoms.

Key Findings

• Tiratricol can enter cells independently of the MCT8 transporter.
• The treatment resulted in decreased elevated thyroid hormone levels in the blood.
• Clinical studies showed improvements in heart rate and systolic blood pressure among treated patients.
• The most common adverse effects included diarrhea, vomiting, rash, and excessive sweating.
• Tiratricol received multiple designations, including Orphan Drug and Breakthrough Therapy.

Clinical Implications

Consult with patients regarding the use of other thyroid medications before initiating treatment with tiratricol.

Conclusion

The approval of tiratricol provides a new therapeutic option for managing MCT8 deficiency.

Related Resources & Content

1. US Food and Drug Administration, FDA, 2026 -- FDA Approves First Treatment for MCT8 Deficiency
2. The Journal of Clinical Endocrinology & Metabolism, 2026 -- Thyrotoxicosis in MCT8 deficiency
3. Frontiers in Pediatrics, 2026 -- Hepatic and Skeletal Muscle Involvement in Monocarboxylate Transporter 8 Deficiency
4. The Journal of Clinical Endocrinology & Metabolism, 2026 -- Treatment with Phenylbutyrate in a Pediatric Patient with MCT8 Deficiency
5. MDSpire News — FDA Approves First Drug for Thymidine Kinase 2 Deficiency
6. FDA Approves First Treatment for MCT8 Deficiency | FDA
7. Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial - PubMed
8. Clinical and Biochemical Monitoring of Monocarboxylate Transporter 8 Deficiency (Allan-Herndon-Dudley Syndrome) across the Lifespan: Practical Considerations for Multidisciplinary Care | Hormone Research in Paediatrics | Karger Publishers